^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Ventana MMR RxDx Panel

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    VENTANA MMR RxDx Panel is a qualitative immunohistochemistry test intended for use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) in formalin-fixed, paraffin-embedded (FFPE) endometrial carcinoma tissue by light microscopy. The OptiView DAB IHC Detection Kit is used for MLH1, MSH2 and MSH6, and the OptiView DAB IHC Detection Kit with the OptiView Amplification Kit is used for PMS2 on a VENTANA BenchMark ULTRA instrument. VENTANA MMR RxDx Panel is indicated as an aid in identifying patients eligible for treatment with JEMPERLI (dostarlimab-gxly)
    Cancer:
    Endometrial Cancer, Solid Tumor
    Gene:
    MLH1 (MutL homolog 1), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), MSI (Microsatellite instability), PMS2 (PMS1 protein homolog 2)
    Drug:
    Jemperli (dostarlimab-gxly), Keytruda (pembrolizumab), Lenvima (lenvatinib)
    Method:
    Immunohistochemistry (IHC)
    Confirmatory trial(s)
    GARNET
    ,
    NCT02715284
    |
    JAMA Oncol